Andreas Wicki

6.5k total citations · 2 hit papers
81 papers, 4.6k citations indexed

About

Andreas Wicki is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Andreas Wicki has authored 81 papers receiving a total of 4.6k indexed citations (citations by other indexed papers that have themselves been cited), including 44 papers in Oncology, 30 papers in Molecular Biology and 23 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Andreas Wicki's work include Cancer Genomics and Diagnostics (9 papers), Colorectal Cancer Treatments and Studies (9 papers) and Lung Cancer Treatments and Mutations (8 papers). Andreas Wicki is often cited by papers focused on Cancer Genomics and Diagnostics (9 papers), Colorectal Cancer Treatments and Studies (9 papers) and Lung Cancer Treatments and Mutations (8 papers). Andreas Wicki collaborates with scholars based in Switzerland, Germany and Italy. Andreas Wicki's co-authors include Vimalkumar Balasubramanian, Jörg Huwyler, Dominik Witzigmann, Gerhard Christofori, François Lehembre, Kenneth J. Clemetson, Dontscho Kerjaschki, Brigitte Hantusch, Nikolaus Wick and Christoph Rochlitz and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and Physiological Reviews.

In The Last Decade

Andreas Wicki

75 papers receiving 4.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Nanomedicine in cancer therapy: Challenges, opportunities, and clinical applications

2014 1.5k citations Andreas Wicki et al. profile →
Biology, vulnerabilities and clinical applications of circulating tumour cells

2022 189 citations Bich Doan Nguyen-Sträuli, Andreas Wicki et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Andreas Wicki Switzerland	27	1.8k	1.5k	1.1k	1.0k	462	81	4.6k
Wayne L. Monsky United States	27	1.7k 0.9×	895 0.6×	1.4k 1.2×	1.6k 1.6×	442 1.0×	84	5.2k
Christopher P. Leamon United States	43	3.2k 1.8×	1.7k 1.1×	1.7k 1.5×	1.3k 1.2×	221 0.5×	94	6.6k
Manohar Ratnam United States	31	2.8k 1.6×	1.1k 0.7×	813 0.7×	522 0.5×	207 0.4×	103	5.5k
Vuong Trieu United States	23	1.2k 0.7×	2.0k 1.3×	969 0.9×	565 0.6×	607 1.3×	92	4.1k
Peter Laverman Netherlands	41	1.6k 0.9×	1.3k 0.8×	1.1k 1.0×	698 0.7×	406 0.9×	123	5.2k
Simon T. Barry United Kingdom	38	2.8k 1.6×	1.4k 0.9×	1.4k 1.2×	1.5k 1.5×	279 0.6×	123	6.1k
Roland Haubner Germany	45	2.7k 1.5×	2.0k 1.3×	381 0.3×	628 0.6×	312 0.7×	93	7.3k
Andrew I. Minchinton Canada	30	2.0k 1.2×	1.4k 0.9×	824 0.7×	1.4k 1.4×	275 0.6×	103	5.1k
Steve R. Roffler Taiwan	42	3.4k 1.9×	1.3k 0.9×	1.1k 1.0×	905 0.9×	172 0.4×	168	6.1k
Jun Qian China	28	1.9k 1.1×	448 0.3×	577 0.5×	514 0.5×	408 0.9×	113	3.5k

Countries citing papers authored by Andreas Wicki

Since Specialization

Citations

This map shows the geographic impact of Andreas Wicki's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andreas Wicki with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andreas Wicki more than expected).

Fields of papers citing papers by Andreas Wicki

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Andreas Wicki. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andreas Wicki. The network helps show where Andreas Wicki may publish in the future.

Co-authorship network of co-authors of Andreas Wicki

This figure shows the co-authorship network connecting the top 25 collaborators of Andreas Wicki. A scholar is included among the top collaborators of Andreas Wicki based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Andreas Wicki. Andreas Wicki is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Rieke, Damian, Michael Bitzer, Annalen Bleckmann, et al.. (2025). Precision oncology – Guideline of the Austrian, German and Swiss Societies for hematology and medical oncology. European Journal of Cancer. 220. 115331–115331.

Peytremann‐Bridevaux, Isabelle, Joachim Marti, Jean‐Luc Bulliard, et al.. (2025). Comparative inpatient care of cancer vs. non-cancer patients in Switzerland during the national COVID-19 lockdown: a nationwide interrupted time series analysis. BMC Cancer. 25(1). 477–477.

Boos, Laura & Andreas Wicki. (2024). The molecular tumor board—a key element of precision oncology. memo - Magazine of European Medical Oncology. 17(3). 190–193. 3 indexed citations

Eicher, Manuela, Isabelle Peytremann‐Bridevaux, Stefan Aebi, et al.. (2024). Identifying the drivers of overall rating of cancer care: Insights from the second wave of the Swiss Cancer Patient Experiences study. Cancer. 130(24). 4334–4346. 1 indexed citations

Wicki, Andreas, et al.. (2024). Frequency and Consequences of Immune Checkpoint Inhibitor–Associated Inflammatory Changes in Different Organs: An Autopsy Study Over 13 -Years. Modern Pathology. 38(4). 100683–100683. 2 indexed citations

Pradervand, Sylvain, Rita Achermann, Simon Haefliger, et al.. (2024). Real-world occurrence, therapy, and outcome of patients with class 2 or 3 BRAF compared with class 1 BRAF-mutated cancers. SHILAP Revista de lepidopterología. 6. 100075–100075. 1 indexed citations

Gnannt, Ralph, Michael Hofmann, Olivier de Rougemont, et al.. (2023). Complication rates of peripherally inserted central catheters vs implanted ports in patients receiving systemic anticancer therapy: A retrospective cohort study. International Journal of Cancer. 153(7). 1397–1405. 8 indexed citations

Bastian, Sara, Markus Joerger, Matthias Gückenberger, et al.. (2022). 431P Neoadjuvant treatment with regorafenib and capecitabine combined with radiotherapy in locally advanced rectal cancer: A multicenter phase Ib trial (RECAP) SAKK 41/16. Annals of Oncology. 33. S731–S732.

Schwab, Fabienne D., Manuel C. Scheidmann, André Kling, et al.. (2022). MyCTC chip: microfluidic-based drug screen with patient-derived tumour cells from liquid biopsies. Microsystems & Nanoengineering. 8(1). 130–130. 17 indexed citations

10.

Britschgi, Christian, Sylvain Pradervand, Rita Achermann, et al.. (2022). Structure-based prediction of BRAF mutation classes using machine-learning approaches. Scientific Reports. 12(1). 12528–12528. 7 indexed citations

11.

Wicki, Andreas, Christoph Mamot, Khalil Zaman, et al.. (2021). 268P Anti-EGFR-immunoliposomes loaded with doxorubicin in patients with advanced triple-negative, EGFR positive breast cancer: A multicenter single arm phase II trial [SAKK 24/14]. Annals of Oncology. 32. S479–S479. 4 indexed citations

12.

Koessler, Thibaud, Salvatore Piscuoglio, Ronny Nienhold, et al.. (2020). Reliability of liquid biopsy analysis: an inter-laboratory comparison of circulating tumor DNA extraction and sequencing with different platforms. Laboratory Investigation. 100(11). 1475–1484. 15 indexed citations

13.

Kunita, Akiko, Vanessa Baeriswyl, Claudia Meda, et al.. (2018). Inflammatory Cytokines Induce Podoplanin Expression at the Tumor Invasive Front. American Journal Of Pathology. 188(5). 1276–1288. 23 indexed citations

14.

Wicki, Andreas, Mario Mandalà, Daniela Massi, et al.. (2016). Acquired Resistance to Clinical Cancer Therapy: A Twist in Physiological Signaling. Physiological Reviews. 96(3). 805–829. 49 indexed citations

15.

Orleth, Annette, Christoph Mamot, Christoph Rochlitz, et al.. (2015). Simultaneous targeting of VEGF-receptors 2 and 3 with immunoliposomes enhances therapeutic efficacy. Journal of drug targeting. 24(1). 80–89. 18 indexed citations

16.

Xue, Gang, Alfred Zippelius, Andreas Wicki, et al.. (2015). Integrated Akt/PKB Signaling in Immunomodulation and Its Potential Role in Cancer Immunotherapy. JNCI Journal of the National Cancer Institute. 107(7). djv171–djv171. 72 indexed citations

17.

Wicki, Andreas, Damian Wild, Rosalba Mansi, et al.. (2014). Synergism of peptide receptor-targeted Auger electron radiation therapy with anti-angiogenic compounds in a mouse model of neuroendocrine tumors. EJNMMI Research. 4(1). 9–9. 4 indexed citations

18.

Wicki, Andreas, Christoph Rochlitz, Annette Orleth, et al.. (2011). Targeting Tumor-Associated Endothelial Cells: Anti-VEGFR2 Immunoliposomes Mediate Tumor Vessel Disruption and Inhibit Tumor Growth. Clinical Cancer Research. 18(2). 454–464. 77 indexed citations

19.

Wicki, Andreas, François Lehembre, Nikolaus Wick, et al.. (2006). Tumor invasion in the absence of epithelial-mesenchymal transition: Podoplanin-mediated remodeling of the actin cytoskeleton. Cancer Cell. 9(4). 261–272. 477 indexed citations

20.

Wicki, Andreas & Gerhard Christofori. (2006). The potential role of podoplanin in tumour invasion. British Journal of Cancer. 96(1). 1–5. 249 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact